Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis

Table 2

Proportional hazard regression model for OS and DSS of MIBC patients by demographic and clinical characteristics: RC vs. TMT.

Characteristics	No. of patients	Overall survival (OS)		Disease-specific survival (DSS)
		HR	95% CI	HR	95% CI
RC-MIBC cohort	891	1.00 [reference]		1.00 [reference]
TMT-MIBC cohort	891	1.17	0.91-1.43	1.20	0.94-1.49
Age at diagnosis
60-69	477	1.24	0.87-1.65	1.25	0.89-1.70
70-79	414	1.08	0.71-1.53	1.10	0.73-1.57
Gender
Men	625	1.19	0.89-1.57	1.21	0.87-1.64
Women	266	1.16	0.69-1.68	1.20	0.70-1.74
Year at treatment
<2010	381	1.05	0.64-1.48	1.04	0.63-1.47
≥2010	510	1.27	0.96-1.51	1.28	0.97-1.61
Clinical T stage
T2-T3a	799	1.03	0.90-1.45	1.06	0.87-1.49
T3b-T4a	92	1.36	0.98-1.87	1.39	0.97-1.99
Charlson Comorbidity Index (CCI)
0-1	548	1.06	0.86-1.50	1.08	0.85-1.53
2 or more	343	1.21	0.83-1.62	1.23	0.81-1.66

Analyses were based on the Cox PH regression. All baseline covariates were well balanced in the propensity score-matched sample according to demographic and clinicopathological characteristics. Therefore, only treatment information was controlled for in the final Cox PH regression model. OS: overall survival; DSS: disease-specific survival; HR: hazard ratio; CI: confidence interval; RC: radical cystectomy; TMT: bladder-sparing trimodality therapy; MIBC: muscle-invasive bladder cancer.